Categories AlphaGraphs, Health Care, U.S. Markets News
Allergan, Mylan and other generics beam as Pfizer loses patent war in the UK
It was good news for generic drug firms such as Allergan (AGN) and Mylan (MYL), as pharma giant Pfizer (PFE) lost a long legal battle in Britain regarding the patents surrounding its hit drug Lyrica.
Pain drug Lyrica — generically: pregabalin — rakes in about $5 billion a year for the drugmaker, and the UK apex court ruled against Pfizer affirming a secondary medical use for the medication.
Years of legal bouts in lower courts finally ended with a defeat, and it is more significant now that the secondary pain patent has expired in Europe.
Pfizer, expressing disappointment at the ruling, said that the outcome was a huge blow to medical innovation incentives.
Pfizer argued that generic drug companies such as Actavis (now, Allergen) and Mylan would be subject to patent infringement on the second patent, despite skinny labeling (generic products labeled only as suitable for treatment of epilepsy and GAD.)
The Supreme Court said it saw Pfizer claims failing “for insufficiency” and overruled the patent plea.
In a gist, the ruling suggests that the patent protection for manufacturing pregabalin — to treat peripheral and central neuropathic pain — was removed.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on